Data updated: Mar 10, 2026
LYVISPAH
BACLOFEN
Approved 2021-11-22
1
Indication
--
Phase 3 Trials
4
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2021-11-22
- Routes
- ORAL
- Dosage Forms
- GRANULES
LYVISPAH Approval History
Loading approval history...
What LYVISPAH Treats
1 FDA approvalsOriginally approved for its first indication in 2021 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LYVISPAH FDA Label Details
ProLYVISPAH Patents & Exclusivity
Latest Patent: Sep 2041
Patents (63 active)
US11850225
Expires Sep 29, 2041
US11491125
Expires Sep 29, 2041
US10792262
Expires Jul 29, 2039
US11654124
Expires Jul 29, 2039
US11931328
Expires Jul 29, 2039
+ 53 more patents
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.